Abstract | OBJECTIVE: METHODS: Varying doses of intravenously administered BPA- fructose (130-250 mg BPA per kilogram of body weight) were given to patients 2 to 3 hours prior to the start of craniotomy for either suspected or known glioblastoma multiforme. Blood samples were collected over a 48-hour period for boron assay. At surgery, multiple samples of tumor, brain, and scalp were obtained for boron and histological analysis. RESULTS: Seventeen patients were studied; all but one had glioblastoma multiforme. No adverse effects from the BPA infusions were noted. The boron concentration in the blood reached a maximum at the end of the BPA infusion and was proportional to the administered dose of BPA. Normal brain concentrations of boron generally were equal to or less than that in blood. Tumor-blood boron ratios were highly variable: 1.6 +/- 0.8 (mean +/- standard deviation; n = 187; range, 0.3-3.5). The observed heterogeneity of BPA uptake in glioblastoma samples appears to correlate with the degree of cellularity observed on histological examination. CONCLUSION:
|
Authors | E H Elowitz, R M Bergland, J A Coderre, D D Joel, M Chadha, A D Chanana |
Journal | Neurosurgery
(Neurosurgery)
Vol. 42
Issue 3
Pg. 463-8; discussion 468-9
(Mar 1998)
ISSN: 0148-396X [Print] United States |
PMID | 9526978
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Boron Compounds
- Radiation-Sensitizing Agents
- Phenylalanine
- 4-boronophenylalanine
|
Topics |
- Boron Compounds
(blood, pharmacokinetics)
- Brain
(metabolism, pathology)
- Brain Neoplasms
(metabolism, pathology, therapy)
- Craniotomy
- Glioblastoma
(metabolism, pathology, therapy)
- Humans
- Injections, Intravenous
- Neutron Capture Therapy
- Osmolar Concentration
- Phenylalanine
(analogs & derivatives, blood, pharmacokinetics)
- Radiation-Sensitizing Agents
(pharmacokinetics)
- Scalp
(metabolism)
- Tissue Distribution
|